Boston Scientific Q3 net sales $4.209B (+19.4% reported), adj. EPS $0.63 vs $0.50 YoY

BOSTON SCIENTIFIC CORP

2024-Q3 EPS reported $0.87 revenue$12,186,000,000

Net sales $4.209B, up 19.4% reported, 18.2% organic; beat guidance of 13-15%.
GAAP EPS $0.32 (down from $0.34), adjusted EPS $0.63 (vs guidance $0.57-0.59).
Cardiovascular segment grew 25.0% reported; MedSurg grew 10.3%.
Full-year 2024 organic sales guidance ~15%; Q4 organic guidance 14-16%.
Completed acquisition of Silk Road Medical for stroke prevention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.